Vanguard Global Advisers
OVID icon

Vanguard Global Advisers’s Ovid Therapeutics OVID Stock Holding History

Vanguard Global Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Buy
70,527
+46,788
+197% +$121K ﹤0.01% 2516
2026
Q1 		$52.7K Buy
+23,739
New +$42.4K ﹤0.01% 2997

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Global Advisers's OVID Position: Q2 2026 in Review

Vanguard Global Advisers increased its Ovid Therapeutics (OVID) stake by 197% in Q2 2026, buying an estimated $121K and bringing the position to 70,527 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Vanguard Global Advisers first reported a position in OVID in Q1 2026 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Vanguard Global Advisers held 70,527 shares of Ovid Therapeutics worth $190K as of Q2 2026.
  • Vanguard Global Advisers bought 46,788 Ovid Therapeutics shares in Q2 2026, an estimated $121K.
  • Ovid Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2516 holding.
  • Vanguard Global Advisers first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.